Skip to main content

Nonalcoholic Fatty Liver Disease (Nafld) in Patients with Laron Syndrome

  • Chapter
  • First Online:
Laron Syndrome - From Man to Mouse
  • 584 Accesses

Core Message

Some obese patients with Laron syndrome develop NAFLD (non-alcoholic fatty liver disease). No clear metabolic correlation could be established.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6:1–28

    Article  PubMed  CAS  Google Scholar 

  • Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504

    Article  PubMed  CAS  Google Scholar 

  • Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100

    Article  PubMed  CAS  Google Scholar 

  • Kanety H, Hemi R, Ginsberg S, Pariente C, Yissachar E, Barchoder E, Funahashi T, Laron Z (2009) Total and high molecular weight adiponectin are elevated in patients with Laron syndrome despite marked obesity. Eur J Endocrinol 161(6):837–44

    Article  PubMed  CAS  Google Scholar 

  • Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, Bass DD (1999) Fatty liver—an additional and treatable feature of the insulin resistance syndrome. QJM 92:73–79

    Article  CAS  Google Scholar 

  • Laron Z (2004) Laron syndrome (primary growth hormone resistance or insensitivity). The personal experience 1958-2003. J Clin Endocrinol Metab 89:1031–1044

    Article  PubMed  CAS  Google Scholar 

  • Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaissman N (2006a) Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol 65:114–117

    Article  CAS  Google Scholar 

  • Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N (2006b) Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res 16:61–64

    Article  PubMed  CAS  Google Scholar 

  • Laron Z, Ginsberg S, Pariente C, Kanety H (2007) Serum adiponectin levels are high in untreated and IGF-I treated patients with Laron syndrome (Abstract #P03-418). Horm Res 68(Suppl 1):128

    Google Scholar 

  • Laron Z, Ginsberg S, Webb M (2008) Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res 18:434–438

    Article  PubMed  CAS  Google Scholar 

  • Laron Z, Kelijman M, Pertzelan A, Keret R, Shoffner JM, Parks JS (1985) Human growth hormone gene deletion without antibody formation or growth arrest during treatment–a new disease entity? Isr J Med Sci 21:999–1006

    PubMed  CAS  Google Scholar 

  • Laron Z, Klinger B (1993) Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm Res 40:16–22

    Article  PubMed  CAS  Google Scholar 

  • Matthews DR, Hosker JP, Rudenski SA, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    Article  PubMed  CAS  Google Scholar 

  • Perlemuter G, Bigorgne A, Cassard-Doulcier A-M, Naveau S (2007) Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nature Clin Pract Endocrinol Metab 3:458–469

    Article  CAS  Google Scholar 

  • Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960

    Article  PubMed  CAS  Google Scholar 

  • Trujillo ME, Scherer PE (2006) Adipose tissue-derived factors: Impact on health and disease. Endocr Rev 27:762–778

    PubMed  CAS  Google Scholar 

  • Webb M, Yeshua H, Zelber-Sagi S, Santo M, Barazovski E, Katz R, Halpern Z, Oren R (2006) A practical index for ultrasonographic quantification of liver steatosis, (Abstract 1230). Hepatology 44 (Suppl):648A

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zvi Laron .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Laron, Z. (2011). Nonalcoholic Fatty Liver Disease (Nafld) in Patients with Laron Syndrome. In: Laron, Z., Kopchick, J. (eds) Laron Syndrome - From Man to Mouse. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11183-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11183-9_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11182-2

  • Online ISBN: 978-3-642-11183-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics